Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last --
Change Today 0.00 / 0.00%
Volume 0.0
ALEMBICLTD On Other Exchanges
ALEMBICLTD is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

alembic ltd (ALEMBICLTD) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALEMBIC LTD (ALEMBICLTD)

Related News

No related news articles were found.

alembic ltd (ALEMBICLTD) Related Businessweek News

No Related Businessweek News Found

alembic ltd (ALEMBICLTD) Details

Alembic Limited researching, developing, manufacturing, and marketing of fermentation and chemistry based active pharmaceuticals ingredients (API). The company operates through API and Real Estate segments. It is also involved in the development, manufacture, and marketing of pharmaceutical products, pharmaceutical substances, and intermediates. The company was founded in 1907 and is based in Vadodara, India.

523 Employees
Last Reported Date: 07/7/15
Founded in 1907

alembic ltd (ALEMBICLTD) Top Compensated Officers

Chief Executive Officer, President of Operati...
Total Annual Compensation: 18.4M
Chief Financial Officer
Total Annual Compensation: 1.3M
Compensation as of Fiscal Year 2015.

alembic ltd (ALEMBICLTD) Key Developments

Alembic Ltd. Approves Dividend for the Year 2014-2015

Alembic Ltd. announced that at the AGM held on August 12, 2015, approved a dividend of INR 0.15 (7.5%) per share of INR 2 each for the year 2014-15.

Alembic Ltd Appoints Drigesh Mittal as Dy. Company Secretary and Compliance Officer

Alembic Ltd. announced that Mr. Drigesh Mittal has been appointed as the Dy. Company Secretary and Compliance Officer of the company with effect from June 15, 2015.

Alembic Limited Reports Unaudited Standalone Earnings Results for the First Quarter Ended June 30, 2015

Alembic Limited reported unaudited standalone earnings results for the first quarter ended June 30, 2015. For the quarter, net sales/income from operation was INR 326.5 million against INR 300.7 million a year ago. Profit from operation before other income, interest and depreciation was INR 44.6 million against INR 58.6 million a year ago. Profit from ordinary activities before tax was INR 33.1 million against INR 39.3 million a year ago. Net profit from ordinary activities after tax was INR 25.6 million or INR 0.10 per basic and diluted share against INR 31.7 million or INR 0.12 per basic and diluted share a year ago. Total income from operations was INR 349.4 million against INR 327.3 million a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALBC:IN 42.65 INR +0.35

ALEMBICLTD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALEMBICLTD.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALEMBICLTD Industry Range
Price/Earnings 48.6x
Price/Sales 7.5x
Price/Book 4.4x
Price/Cash Flow 39.7x
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALEMBIC LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at